Bristol-Myers Squibb (BMY) | Stock Overview & Key Data
Bristol-Myers Squibb Performance Comparison
Stock Range
Today's Range
Low: $45.66
High: $47.38
on October 2, 2025
52 Week Range
Low: $42.96
High: $63.33
on July 31, 2025
on March 11, 2025
All-Time High: $81.44 on November 28, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$89.9B
EPS
2.49
P/E Ratio (TTM)
17.73
Forward P/E
6.28
P/B Ratio
5.15
PEG Ratio
-0.77
Div. Yield
N/A
ROE
29.32%
Beta
0.357
Debt to Equity
291.55
Financial Highlights
Profitability
Gross Margin
72.52%
Operating Margin
33.68%
Profit Margin
10.58%
Returns and Earnings
Return on Assets (TTM)
8.33%
Return on Equity (TTM)
29.32%
EBITDA
$18.3B
Net Income (TTM)
$5.0B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$23.51
Quarterly Revenue Growth (YoY)
0.60%
Quarterly Earnings Growth (YoY)
-22.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb BMY | 89.86B Large-cap | 5.34% | -3.54% | -3.99% | -23.27% | -19.48% | -15.25% | -34.39% | -26.03% |
| Eli Lilly and LLY | 658.23B Mega-cap | 14.73% | 11.52% | 5.21% | 0.20% | 5.37% | -7.59% | 150.98% | 422.60% |
| Johnson & Johnson JNJ | 437.40B Mega-cap | 4.64% | 4.45% | 19.56% | 19.71% | 29.13% | 16.03% | 16.09% | 23.19% |
| Amgen AMGN | 160.11B Large-cap | 9.67% | 3.65% | 0.19% | -2.72% | 14.70% | -6.96% | 29.85% | 25.64% |
| Pfizer PFE | 147.88B Large-cap | 14.75% | 8.41% | 6.95% | 9.64% | 1.77% | -5.25% | -36.01% | -22.43% |
| Gilead Sciences GILD | 139.74B Large-cap | -0.39% | -1.91% | -0.85% | -1.19% | 20.33% | 30.70% | 71.97% | 73.18% |
Ownership & Short Interest
Insider Ownership
0.07%
Institutional Ownership
82.79%
Shares Short
29M
Short Ratio
3.05
Short % of Shares Outstanding
1.45%
Average 10-Day Volume
18M
Average 90-Day Volume
12M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BMY's 52-week high and low?
- In the last 52 weeks, Bristol-Myers Squibb reached a high of $63.33 (on March 11, 2025) and a low of $42.96 (on July 31, 2025).
- What is the market cap and P/E ratio for BMY?
- Curious about Bristol-Myers Squibb's size and valuation? Its market capitalization stands at 89.86B. When it comes to valuation, the P/E ratio (trailing twelve months) is 17.73, and the forward P/E (looking ahead) is 6.28.
- Does BMY pay dividends? If so, what's the yield?
- As for dividends, Bristol-Myers Squibb isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Bristol-Myers Squibb's main competitors or similar companies to consider before investing?
When looking at Bristol-Myers Squibb, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY658.23B Healthcare Drug Manufacturers - General -7.59% 150.98% Johnson & Johnson
JNJ437.40B Healthcare Drug Manufacturers - General 16.03% 16.09% Amgen
AMGN160.11B Healthcare Drug Manufacturers - General -6.96% 29.85% Pfizer
PFE147.88B Healthcare Drug Manufacturers - General -5.25% -36.01% Gilead Sciences
GILD139.74B Healthcare Drug Manufacturers - General 30.70% 71.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bristol-Myers Squibb Company? (e.g., ROE, Debt/Equity)
- To get a sense of Bristol-Myers Squibb's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 29.32%, the Debt to Equity ratio from the most recent quarter is 291.55, and its Gross Profit Margin stands at 72.52%.
- What is the recent revenue and earnings growth for BMY?
- Looking at Bristol-Myers Squibb's growth, its revenue over the trailing twelve months (TTM) was $48B. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.60%, and quarterly earnings saw a YoY growth of -22.00%.
- How much of BMY stock is held by insiders and institutions?
- Wondering who owns Bristol-Myers Squibb stock? Company insiders (like executives and directors) hold about 0.07% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 82.79%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.